- Ticker
- ABCL
- Price
- 11.85
- Stock movement up
- +0.38 (3.31%)
- Company name
- Abcellera Biologics Inc
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 3.37B
- Ent value
- 3.21B
- Price/Sales
- 6.89
- Price/Book
- 101.78
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- 16.46
- Forward P/E
- -
- PEG
- -
- EPS growth
- -
- 1 year return
- -30.54%
- 3 year return
- -
- 5 year return
- -
- 10 year return
- -
Last updated: 2022-08-25
DIVIDENDS
ABCL does not pay dividends
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | 16.46 |
| Price to OCF | 14.33 |
| Price to FCF | 20.32 |
| Price to EBITDA | 10.99 |
| EV to EBITDA | 10.47 |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 6.89 |
| Price to Book | 101.78 |
| EV to Sales | 6.57 |
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 284.54M |
| EPS (TTM) | 0.73 |
| FCF per share (TTM) | 0.59 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 489.06M |
| Gross profit (TTM) | 463.56M |
| Operating income (TTM) | 271.37M |
| Net income (TTM) | 204.82M |
| EPS (TTM) | 0.73 |
| EPS (1y forward) | -0.48 |
Margins
Loading...
Margins data
| Gross margin (TTM) | 94.79% |
| Operating margin (TTM) | 55.49% |
| Profit margin (TTM) | 41.88% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 545.72M |
| Net receivables | 334.40M |
| Total current assets | 1.17B |
| Goodwill | 47.81M |
| Intangible assets | 145.78M |
| Property, plant and equipment | 0.00 |
| Total assets | 1.59B |
| Accounts payable | 10.35M |
| Short/Current long term debt | 40.28M |
| Total current liabilities | 213.42M |
| Total liabilities | 384.78M |
| Shareholder's equity | 33.13M |
| Net tangible assets | 1.01B |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | 235.26M |
| Capital expenditures (TTM) | 69.30M |
| Free cash flow (TTM) | 165.96M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | 618.24% |
| Return on Assets | 49.01% |
| Return on Invested Capital | 618.24% |
| Cash Return on Invested Capital | 500.94% |
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 11.53 |
| Daily high | 11.97 |
| Daily low | 11.38 |
| Daily Volume | 1.20M |
| All-time high | 53.20 |
| 1y analyst estimate | 30.00 |
| Beta | - |
| EPS (TTM) | 0.73 |
| Dividend per share | - |
| Ex-div date | - |
| Next earnings date | 7 Nov 2022 |
Downside potential
Loading...
Downside potential data
| ABCL | S&P500 | |
| Current price drop from All-time high | -77.73% | -13.41% |
| Highest price drop | -89.25% | -56.47% |
| Date of highest drop | 11 May 2022 | 9 Mar 2009 |
| Avg drop from high | -62.69% | -11.38% |
| Avg time to new high | 86 days | 12 days |
| Max time to new high | 395 days | 1805 days |
COMPANY DETAILS
Marketcap
3.37B
Marketcap category
Mid-cap
Description
AbCellera Biologics Inc. develops antibody discovery platform. Its full-stack, artificial intelligence-powered antibody discovery platform searches and analyzes the database of natural immune systems to find antibodies that could be developed as drugs. As of December 31, 2021, the company had 156 discovery programs that are either completed, in progress, or under contract with 36 partners. AbCellera Biologics Inc. has a research collaboration and license agreement with Eli Lilly and Company. The company was incorporated in 2012 and is headquartered in Vancouver, Canada.
Employees
400
Website
Investor relations
-
SEC filings
CEO
Country
USA
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
All newsPress releases
VANCOUVER, British Columbia, September 21, 2022--AbCellera Launches Second Phase of Global Headquarters Expansion to Advance Capabilities for Bringing New Medicines from Target to the Clinic
September 21, 2022
Those following along with AbCellera Biologics Inc. ( NASDAQ:ABCL ) will no doubt be intrigued by the recent purchase...
August 24, 2022
Investors need to pay close attention to AbCellera (ABCL) stock based on the movements in the options market lately.
August 18, 2022
The contract drug developer's stock is finally shaking off the froth of its initial public offering.
August 10, 2022
Image source: The Motley Fool. AbCellera Biologics Inc. (NASDAQ: ABCL)Q2 2022 Earnings CallAug 09, 2022, 5:00 p.m. ETContents: Prepared Remarks Questions and Answers Call Participants Prepared Rema...
August 10, 2022
AbCellera Biologics Inc. (ABCL) delivered earnings and revenue surprises of -150% and 40%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
August 9, 2022
VANCOUVER, British Columbia, August 09, 2022--AbCellera (Nasdaq: ABCL), a technology company with a centralized operating system for next-generation antibody discovery, today announced financial resul...
August 9, 2022
Eton Pharmaceuticals, Inc. (ETON) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
August 4, 2022
VANCOUVER, British Columbia & CAMBRIDGE, Mass., August 03, 2022--AbCellera and Atlas Venture Collaborate to Empower the Development of Impactful Medicines for Patients
August 3, 2022
AbCellera Biologics Inc. (ABCL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
August 2, 2022
Next page